Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis

Immunologic Research

Volumn 58, Issue 1, 2014, Pages 118-124

  Su, Zhaoliang ^a,b   Sun, Yingkun ^b   Zhu, Haitao ^b   Liu, Yueqin ^a   Lin, Xin ^a   Shen, Huiling ^c   Chen, Jianguo ^c   Xu, Wenlin ^a   Xu, Huaxi ^a,b  

^a The Fourth Affiliated Hospital of Jiangsu University   (China)

^b JIANGSU UNIVERSITY   (China)

^c AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Gastric cancer; Th1; Th17

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR GAMMA T; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TH1 CELL; TH17 CELL; UPREGULATION;

ADENOCARCINOMA; CELL GROWTH PROCESSES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893745145     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8483-y     Document Type: Article

References (31)

1. Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79-84. doi: 10.1007/s10875-012-9847-0.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44. doi: 10.1038/nature07205.
3. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267(2):204-15. doi: 10.1016/j.canlet.2008.03.028.
4. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res. 2010;20(1):4-12. doi: 10.1038/cr.2009.138.
5. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-69. doi: 10.1182/blood-2008-05-078154.
6. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5. doi: 10.1189/jlb.0306164.
7. Kimura A, Kishimoto T. Th17 cells in inflammation. Int Immunopharmacol. 2011;11(3):319-22. doi: 10.1016/j.intimp.2010.10.004.
8. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8-18. doi: 10.1016/j.ajpath.2012.03.044.
9. Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol. 2011;32(12):603-11. doi: 10.1016/j.it.2011.08. 003.
10. Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol. 2013;182(1):10-20. doi: 10.1016/j.ajpath.2012. 08.041.
11. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 2010;10(4):248-56. doi: 10.1038/nri2742.
12. Kryczek I, Wei S, Gong W, Shu X, Szeliga W, Vatan L, et al. Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development. J Immunol. 2008;181(9):5842-6.
13. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114(6):1141-9. doi: 10.1182/blood-2009-03-208249.
14. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86(5):1065-73. doi: 10.1189/jlb.0609385.
15. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF. Generation and regulation of human CD4+IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA. 2008;105(40):15505-10. doi: 10.1073/pnas.0710686105.
16. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219-40. doi: 10.1016/j.gtc.2013.01.003.
17. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14 Suppl 2:ii31-6.
18. Lilienfeld A. Epidemiology of gastric cancer. New Engl J Med. 1972;286(6):316-7. doi: 10.1056/NEJM197202102860610.
19. Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32(6):1332-9. doi: 10.1007/s10875-012-9718-8.
20. Yamada Y, Saito H, Ikeguchi M. Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J Surg Res. 2012;178(2):685-91. doi: 10.1016/j.jss.2012.07.055.
21. Li Q, Li Q, Chen J, Liu Y, Zhao X, Tan B, et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep. 2013;. doi: 10.3892/or.2013.2570.
22. Su Z, Sun C, Zhou C, Liu Y, Zhu H, Sandoghchian S, et al. HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol. 2011;41(12):3586-95. doi: 10.1002/eji.201141879.
23. Greten TF, Zhao F, Gamrekelashvili J, Korangy F. Human Th17 cells in patients with cancer: Friends or foe? Oncoimmunology. 2012;1(8):1438-9. doi: 10.4161/onci.21245.
24. Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, et al. Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol. 2013;190(11):5894-902. doi: 10.4049/jimmunol. 1203141.
25. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008;454(7202):350-2. doi: 10.1038/nature07021.
26. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113. doi: 10.1111/j.1600-065X.2008.00628.x.
27. Backert S, Clyne M, Tegtmeyer N. Molecular mechanisms of gastric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal CCS. 2011;9:28. doi: 10.1186/1478-811X-9-28.
28. Asaoka Y, Ikenoue T, Koike K. New targeted therapies for gastric cancer. Expert Opin Investig Drugs. 2011;20(5):595-604. doi: 10.1517/13543784.2011. 566863.
29. Watanabe M, Kato J, Inoue I, Yoshimura N, Yoshida T, Mukoubayashi C, et al. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer. 2012;131(11):2632-42. doi: 10.1002/ijc.27514.
30. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910-4. doi: 10.1074/jbc.M207577200.
31. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24(2):179-89. doi: 10.1016/j.immuni.2006.01.001.